A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy
In the Italian setting, mosunetuzumab is a cost-effective treatment option compared to tisagenlecleucel for adult patients with R/R 3L+ FL, presenting favourable outcomes from the perspective of the NHS. Future research and data collection efforts are crucial to validate these findings and reduce uncertainties regarding long-term clinical and economic implications.
Authors
- Alice Sabinot (ORCID: https://orcid.org/0000-0002-8645-0584)
- Antonio Pinto (ORCID: https://orcid.org/0000-0002-9425-9026)
- Benedetta Puccini
- Lorenzo Pradelli (ORCID: https://orcid.org/0000-0002-7648-8917)
- Marco Bellone (ORCID: https://orcid.org/0000-0002-6976-5509)
- Emanuela Omodeo Salè (ORCID: https://orcid.org/0000-0002-7641-8708)
- Alessandro D’Arpino
- Stefano Luminari
Institutions
- University of Modena and Reggio Emilia (IT)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ospedale Santa Maria (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
- Misericordia University (US)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ceor.s509907
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05